Pfizer Inc. (NYSE:PFE – Get Free Report) saw unusually large options trading activity on Thursday. Traders acquired 251,131 ...

Pfizer Inc. closed 16.17% below its 52-week high of $31.54, which the company achieved on July 30th.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

Pharmaceutical stocks can bring an element of safety to your portfolio. Why is this the case? These companies make drugs ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

Ritholtz Wealth Management decreased its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 39.4% during the 4th ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Stocks have gotten off to a mixed start in 2025, but a third straight year of gains isn’t out of the question.